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Background: Ubiquitous system of regulatory, calcium-dependent, cytoplasmic proteases – calpains – and their
endogenous inhibitor – calpastatin – is implicated in the proteolytic regulation of activation, proliferation, and
apoptosis of many cell types. However, it has not been thoroughly studied in resting and activated human
lymphocytes yet, especially in relation to the subjects’ ageing process. The CALPACENT project is an international
(Polish-Italian) project aiming at verifying the hypothesis of the role of calpains in the function of peripheral blood
immune cells of Polish (Pomeranian) and Italian (Sicilian) centenarians, apparently relatively preserved in comparison
to the general elderly population. In this preliminary report we aimed at establishing and comparing the baseline
levels of expression of μ- and m-calpain and calpastatin in various, phenotypically defined, populations of human
peripheral blood lymphocytes for healthy elderly Sicilians and Poles, as compared to these values observed in
young cohort.
Results: We have found significant differences in the expression of both μ- and m-calpain as well as calpastatin
between various populations of peripheral blood lymphocytes (CD4+, CD8+ and CD19+), both between the age
groups compared and within them. Interestingly, significantly higher amounts of μ- and m-calpains but not of
calpastatin could be demonstrated in the CD4+CD28- and CD8+CD28- lymphocytes of old subjects (but not in the
cells of young individuals), as compared to their CD28+ counterparts. Finally, decreased expression of both calpains
in the elderly T cells is not related to the accumulation of effector/memory (CD45RO+) cells in the latter, as the
expression of both calpains does not differ significantly between the naïve and memory T cells, while is significantly
lower for elderly lymphocytes if both populations are taken separately.
Conclusions: Observed differences in the amounts of CCS member proteins between various populations of
lymphocytes of young and elderly subjects may participate in the impaired proliferative activity of these cells in the
elderly.
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The ubiquitous, cytoplasmatic calpain-calpastatin system
(CCS) consists of a group of cysteine proteases known as
calpains and of their endogenous inhibitor - calpastatin.
Calpains are extremely calcium-dependent, as their
proteolytic activity requires a sufficiently high concentration
of calcium ions, usually much higher than that observed in
the cytoplasm of resting cells [1,2]. Calpain family
consists of a classic pair of the enzymes (μ-calpain
and m-calpain-see below) that do not exhibit tissue
specificity and are therefore referred to as the ‘typical’
and ‘ubiquitous’, and a larger group of tissue - specific
calpains, occurring only in certain organs. Their respective
names - μ-calpain (calpain I) and m-calpain (calpain II) -
reflect the respective in vitro Ca2+ concentrations required
for full proteolytic activity; μ-calpain respectively requires
1–100 μM Ca2+ and m-calpain 0.1 - 1 mM Ca2+ [3]. On
the other hand, calpastatin is the only natural, endogenous,
and first of all specific inhibitor of calpains, coexisting with
the enzymes and exerting no significant influence on other
enzymes [3-5]. Together, the two ubiquitous calpains and
calpastatin, remaining in a precarious balance within
cytoplasm, form the CCS system.
Physiological relevance of calpains has already been
recognized. Their importance for cellular physiology stems
from their already known substrate list on one side and
their modus operandi on the other. Thus, literally hundreds
of cellular proteins from virtually all functional families had
been shown to undergo calpain-dependent cleavage; yet,
although calpains can completely hydrolyze some of their
substrates, against most of them they do not operate like a
normal protease, but by limited hydrolysis of only one or a
few sites in the substrate molecule they modulate its activity
and function [1,6,7]. This “biomodulation” of calpain
substrates (controlled by internal balance within the CCS
on one side, and by the momentous levels of cytoplasmic
[Ca2+] on the other) can affect the generation and
transduction of signals leading to cell proliferation,
functional activation or apoptosis [8-10]. CCS system
activity has already been implicated in the pathologies
ranging from Alzheimer’s disease to muscular dystrophies
to multiple sclerosis to cancers [10-13]. Its recognized
physiological roles make it a potentially important regulator
of the immune response.
We have recently demonstrated that calpain activity is
increased in the B-CLL leukemic cells [14], in the CD4+ T
cells of rheumatoid arthritis patients [15] and in acute
childhood leukemia blasts (in preparation). We also
have preliminarily data suggesting the same for CD4+
lymphocytes of healthy elderly. Thus it is feasible that
the system may be involved (beneficially or otherwise)
in the functioning of T lymphocytes and its deregulation
or disruption may impact on or participate in more
general way in the process of immune system ageing,affecting also other populations of the immune cells. In
the available literature there are no data on the relative
abundance or activity of the CCS members in human
blood lymphocytes in relation to ageing.
Centenarians (technically people whose lifespan
extended beyond 95 years of age) are thought to be a
(genetically? environmentally?) selected group of human
beings ageing extremely successfully [16,17]. Their
successful ageing implies also relatively good state of
their immune systems. As the latter heavily depend on the
timely and balanced activation, proliferation, secretion
and ultimately apoptotic death of many interrelated
and cooperating subpopulations of the adaptive
immune system, we proposed a hypothesis of different
activity of the CCS in the immune cells of centenarians
(as compared to younger healthy elderly and to the
healthy young cohort). Study of this hypothesis is the goal
of the Polish-Italian CALPACENT project. In more detail,
its overall aim is to compare the relative abundances,
activities and roles of CCS member proteins in various
peripheral blood lymphocyte populations from Polish
(Pomeranian) and Italian (Sicilian) centenarians with those
observed in elderly and young cohorts. This preliminary
report provides the baseline values of expression of the
CCS system members in major T and B lymphocytes
populations of young and elderly cells, as a starting
point for its more detailed characteristics.
Methods
A total of 26 healthy individuals (proportionally from
Poland and Italy) were included in the study, divided
into two groups: young (4 men and 6 women, age range:
26–38, median 29,5 years) and old (6 men and 10 women,
age range: 76–95, median 86,5 years). All subjects were in
good health according to their clinical history and none of
them had infectious, inflammatory, neoplastic or auto-
immune diseases at the time of the study. The study was
approved by both Polish and Italian committees for ethics
in biomedical research at the partners’ institutions; the
subjects were informed about the purpose of the study and
about their own involvement and gave their consent.
Whole blood samples were obtained in Vacutainer™
tubes containing ethylenediamine-tetraacetic acid (EDTA).
Peripheral blood mononuclear cells (PBMC) were
isolated by density gradient centrifugation on Lympholyte®
(Cedarlane, Canada) and directly immunostained with
antibody conjugates detecting the following lymphocyte
antigens: CD4-PE-Cy5, CD8-PE-Cy5 (DAKO, Denmark)
and CD28-PE, CD45RA-PE, CD45RO-PE-CF594 (Becton–
Dickinson, USA) - for T lymphocytes and CD19-PE-Cy5
(DAKO, Denmark), CD40-PE (Becton–Dickinson, USA) -
for B cells. Then intracellular labeling of CCS member
proteins was performed with anti: μ-calpain, m-calpain
and calpastatin (all GeneTex, USA) after fixation and
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buffer and 0.25% saponin (Sigma Aldrich, Germany)
in PBS. All three primary anti-CCS antibodies were
conjugated with Mix-n-Stain CF555 antibody labeling
kit (Biotium, Inc., USA) yielding the conjugate fluorescence
identical with that of FITC. This technique produces
antibodies that are uniformly conjugated to the same
fluorochrome, thus allowing for semi-quantitative analysis
and interpretation of the resulting fluorescence values.
Determination of the net values of the mean fluorescence
intensities (MFIs) of the CCS protein-bound antibodies was
done using fluorescence-minus-one (FMO) controls.
This technique allowed to determine the ‘negative’
MFIs (from samples stained with all conjugated antibodies
minus the CF555-conjugated anti-CCS ones) to be
subtracted from the relevant ‘total’ MFIs of the samples
stained with all antibodies including the CF555-conjugated
anti-CCS).
Negative control for surface phenotype staining was
achieved by staining of parallel samples with: isotype-PE,
isotype-PE-Cy5 (both IgG1), isotype-PE (IgG2b), and
isotype-PE-CF594 (IgG2a) (all Becton–Dickinson, USA).
All measurements were made with FACScalibur Flow
Cytometer (Becton–Dickinson, San Jose, CA, USA); at
least 104 cells were acquired from each sample using the
CellQuest™ software of the instrument and then analyzed
using the Cyflogic™ v. 1.2.1 software. At analysis, the
lymphocytes were first identified by forward and side
scatter gating and then by CD4, CD8, CD19 expression,
respectively.
All statistical analyses were performed with STATISTICA
10™ using either the parametric t tests to compare two
independent groups (relative to the groups or to the
variable) after confirming the normality of data distribu-
tion or Mann–Whitney U test for data deviating from
normal distribution. Statistical significance was expressed
as p<0.05, as shown in the figures. All values are expressed
as mean± standard deviation (SD).
Results
Despite relatively small group of tested individuals
(altogether just 10 young and 16 old people), we were
already able to demonstrate highly significant (p<0.001)
decreases in the amounts of both μ- and m-calpain in
peripheral blood T (CD4+, CD8+) lymphocytes of old
individuals as compared to young people (Figure 1 A, B).
Interestingly, significant differences in the amount of both
μ- and m-calpain could be seen between the CD4+ and
CD8+ lymphocytes of both young and old individuals, with
the respective amount being significantly higher for the
CD8+ cells (Figure 1 A, B). Weaker, but still significant
(p<0.05) differences were also found for calpastatin levels,
showing a decrease in the CD8+ lymphocytes of elderly as
compared to young subjects, as well as a significantlyhigher amount of this inhibitory protein in the CD8+ than
in CD4+ lymphocytes of young people (Figure 1C).
It is well known that with advanced age the proportions
of T lymphocytes expressing the CD28 costimulatory
molecule significantly drop [18]. Thus, observed differences
between the expression of CCS member proteins in young
and elderly subjects could be the result of decreased
proportion of both CD4+CD28+ and CD8+CD28+ cells
(and simultaneous rise in their CD28- counterparts).
For the elderly, the median proportion of CD4+CD28-
lymphocytes was 7.64% (interquartile range 5.57 – 26.22
percent), while corresponding values for the young sub-
jects were 3.38% (1.48 – 6.04%) respectively. Despite
strong and expected trend towards higher percentage of
CD28--ve population among the CD4+ lymphocytes in the
elderly, the difference had not reached statistical signifi-
cance, possibly due to high variability of the results in the
elderly group (Mann–Whitney U test, p=0.078). Similar
strong, but not significant (p=0.261) trend was observed
when the proportions of CD8+CD28- lymphocytes were
compared. For the elderly, the median proportion of this
population was 66.59% (25.02 – 72.14%), while for the
young subjects it was 29.4 (19.29 – 46.26) %. Therefore,
we have compared the relative levels of expression of the
three CCS member proteins separately in CD28+ and
CD28- subpopulations of CD4+ and CD8+ lymphocytes
(Figure 2). Here, the most striking observations concern
significantly higher expression of μ-and m-calpain in the
CD4+CD28- then in the CD4+CD28+ lymphocytes of old
individuals (Figure 2A, B). There are no such differences if
the Tcells of young individuals are considered. Interestingly,
significantly lower expression of both calpains in the
CD4+ and CD8+ cells of elderly subjects shown in the
Figure 1 is preserved in both subpopulations of these
cells differing in CD28 expression; thus, regardless of
being CD28+ or CD28-, the lymphocytes of both lineages of
the elderly express significantly less μ- and m-calpain than
those derived from young individuals (Figure 2A, B, D, E).
Weakly significant drop in the amount of calpastatin could
only be demonstrated when the levels of this inhibitor were
compared between CD8+CD28+ and CD8+CD28-, but not
between CD4+CD28+ and CD4+CD28- lymphocytes of
young and elderly subjects (Figure 2 C, F).
Ageing of the adaptive immune system is also associ-
ated with the increased proportion of effector/memory
(CD45RO+) at the expense of naïve (CD45RA+) lympho-
cytes within the CD4+ population [18]. Thus, it was feasible
that the observed changes in the CCS expression in the
CD4+ cells of the elderly would be due to rising proportion
of the CD45RO+ cells. In the investigated subjects a strong,
statistically significant (Mann–Whitney U test, p=0.0132)
difference was shown when the proportions of memory
CD4+CD45RO+ lymphocytes were compared. Thus,
median value for this proportion for young subjects was
Figure 1 Significant differences in the amounts of μ- (A) and m-calpain (B) and of calpastatin (C) between various populations of peripheral
blood T, but not B lymphocytes (white bars - CD4+, black bars - CD8+ and patterned bars - CD19+) of young and old subjects. Results are
shown as bars for means and whiskers for +/−SD. Statistical significance is indicated by asterisks at p<0.05 (*) or p<0.001 (**). See Methods for the details.
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and for the elderly subjects it was 59.13 (49.21 – 65.07) %
respectively. Therefore, we have checked if these memory
cells differ from CD45RA+ lymphocytes with respect to
the expression of any of the CCS members. As shown in
the Figure 3, there were no differences in the expression
of both μ- and m-calpain between the naïve and effector/
memory cells, regardless the age of cell donor. The naïve
(CD45RA+) subpopulation of the CD4+ cells derived
from elderly exhibited significantly lower amounts of
both calpains and of calpastatin than cells of young
people (Figure 3 A,B,C).
Discussion
Ageing of the adaptive immune system manifests as
increased prevalence of infections, neoplasms and
autoimmune diseases in the elderly and aged cohorts
as compared to young and even middle-aged individuals.
At the cellular level, multiple shifts in the proportions of
lymphocytes exhibiting various phenotypes are observed,
notably increased proportions of the effector/memory and
TEMRA cells at the expense of naïve lymphocytes.
Accompanying (and, presumably, causatively underlying)
functional changes in the lymphocytes of elderly
people include overall lower efficiency of proliferation
to antigen and mitogen challenges in vitro, decreased
production of multiple cytokines and increased proportions
of lymphocytes undergoing activation-dependent apoptosis
(AICD) [18,19]. We have shown before, that the dynamics
of the cell cycle in the CD4+ lymphocytes of aged people
exhibits significant elongation of the time between
onset of stimulation and beginning of the first G1
phase of the first division cycle (the G0→G1 time) in
a manner dependent on the level of costimulatory
CD28 molecule on the surface of these cells, as well
as shortening of the G1 phases of the ensuing division
cycles, associated with increased amounts of cyclin D1
bound to the cyclin-dependent kinases (i.e. active) [19].The calpain-calpastatin system (CCS), consisting of two
ubiquitous cellular proteases (μ- and m-calpain) and their
endogenous inhibitor – calpastatin [1-5] is commonly
acknowledged to variably regulate multiple cellular
activities, including proliferation and apoptosis, by
token of calpains’ ability to modulate the activities of
the involved proteins by cleaving only their regulatory
domains [1-10]. One of the important substrates of
calpains is cyclin D1, a member of cyclin D family
deciding the timing and progression of the G1 phase
of the cell cycle [20]. Thus it was feasible, that the
activity of CCS would be modified in the immune cells of
healthy elderly. Both ubiquitous calpains and calpastatin
are universally expressed in human T lymphocytes
(there are no ‘calpain-negative’ T cells [15]) and their
functions in these cells are involved in modifying the
differentiation of Th1, Th2 and Th17 cells [21] and in
NF-kB-dependent activation [22], as well as in the
regulation of the level of ZAP70 [23]. We have shown
before a strong, ageing-dependent decrease in the
available activity of μ-calpain assessed by casein
zymography in the lysates of total (unseparated) peripheral
blood lymphocytes [14]. However, to date only that one
and our another paper on age-dependent changes in the
CD4+ lymphocyte cell cycle dynamics cited above [19] as
well as a paper from another group indirectly suggesting
the involvement of calpain activity in the B cell precursor
senescence in mice [24] have been published on the topic
of calpain involvement in the lymphocyte ageing.
In this preliminary paper we attempted to compare
the expression of μ- and m-calpain and calpastatin
(forming the CCS system of limited regulatory proteolysis)
in the major populations of human peripheral blood
lymphocytes derived from healthy young and elderly
Sicilian and Polish subjects, as a pilot study for an
international, Polish-Italian project CALPACENT, aiming
at qualitative, quantitative and functional comparison/
assessment of the CCS in centenarian versus the general
Figure 2 Significantly decreased amounts of both μ- (A,D) and m-calpain (B,E) in the CD4+ (A,B) and CD8+ (D,E) as well as of
calpastatin (only in the CD8+; C,F) lymphocytes of old people regardless the expression or lack of CD28. Significantly higher amounts of
both calpains in the CD4+CD28- vs. CD4+CD28+ of old people (A,B) but not in CD8+CD28- vs. CD8+CD28+ (D,E) lymphocytes of young as well as
old subjects. Results are shown as bars for means (CD28+ (□) and CD28- (■) cells respectively) and whiskers for +/− SD. Statistical significance is
indicated by asterisks at p<0.05(*) or p<0.001 (**). See Methods for the details.
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numbers of individuals tested so far, we were able to show
that all three member proteins of the CCS are detectable
and relatively quantifiable by flow cytometry, and that their
expression is significantly lower in the T cells of elderly
subjects, regardless their phenotypic characteristics. Thus
we can conclude that ageing-associated decrease in the
amounts of CCS member proteins in the peripheral
blood T (but not B) lymphocytes is a universal
phenomenon. This decrease was the most prominent
for the CD8+ lymphocytes; on average, the decrease
of the amount was by 60% for μ-calpain, and by 50%
for m-calpain and calpastatin, where the same figures forFigure 3 Significantly decreased amounts of μ- and m-calpain and ca
(■ CD45RO+) subpopulations of CD4+ helper lymphocytes of old com
two subpopulations regarding the CCS protein amounts. Results are sh
is indicated by asterisks at p<0.05(*) or p<0.001 (**). See Methods for the dCD4+ cells were 45%, 40% and only 20% respectively. These
figures show the trend towards a major difference; however,
they did not reach statistical significance, probably due to
too small numbers of subjects studied.
The latter finding may be of potential significance
(drop in calpain without or with only a slight simultaneous
drop in calpastatin levels in the CD4+ cells shifts the
stoichiometry within the CCS, making possible loss of total
and momentous calpain activities due to relative excess of
the endogenous inhibition); it was recently shown that
calpastatin overexpression suppresses production of IL-6
and development of Th17 lymphocytes and thus is anti-
inflammatory [21]. Reduction of calpains’ expressionlpastatin in the naive (□ CD45RA+) and effector/memory
pared to young subjects, and lack of differences between these
own as bars for means and whiskers for +/− SD. Statistical significance
etails.
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similar effect, thus possibly acting as a homeostatic
countermeasure against increased inflammatory readiness
in the aged individuals (inflamm-ageing).
As ageing of the immune system is associated with an
increase in the proportion of CD4+CD28- cells at the
expense of CD4+CD28+ lymphocytes on one side, and with
rising proportions of memory CD45RO+ lymphocytes at
the expense of naïve CD45RA+ ones, it was conceivable that
the differences in the amounts of CCS proteins demon-
strated between young and elderly subjects would stem
from changed proportions of the abovementioned subpopu-
lations. However, the only significant difference concerning
the CCS protein amounts between major age-dependent
differences in the cellular abundance of member proteins of
the CCS could be shown for μ- and m-calpain between the
CD28+ versus CD28- within the CD4+ population of old
people; no such difference could be seen when lymphocytes
differing in CD28 expression was compared for young
individuals, nor within the CD8+ population.
These observations mean that the rate of ageing-
associated decrease in the calpain amounts in the
CD4+CD28+ lymphocyte population is higher than in the
CD4+CD28- counterparts. The CD4+CD28- lymphocytes
are suggested to acquire their phenotype in relation to
increased proinflammatory state of the individual
(notably increased levels of TNF [25]), and themselves
participate in inflammatory processes including rheumatoid
arthritis, chronic kidney disease and atherogenesis [26-29].
It was suggested that TNF augments the expression and
activity of calpains and that its proinflammatory activity is
partially dependent on calpain activation [30]. Thus, rela-
tively retained levels of calpains in CD4+CD28- cells of the
aged (as compared to these levels in the CD4+CD28+ cells)
may be a consequence of higher response of the former to
TNF following the concept of inflamm-ageing [31]. Why
such differences could not be demonstrated for the
CD8+CD28+ and CD8+CD28- cells of the elderly
(showing uniform drop in CCS proteins’ expression
with advanced age) remains a mystery; however one is
tempted to speculate, that the appearance of CD8+CD28-
lymphocytes is relatively less dependent on the activity of
TNF and that the reaction of the CCS system follows suit.
On the other hand, the expected (and duly observed
here), significant age-related increase in the proportion of
CD4+CD45RO+ memory lymphocytes is of no consequence
for the overall decrease in the amount of calpains, as we did
not show any difference in the enzymes’ amounts between
the naïve and memory lymphocytes.
The important question remaining is what is the
physiological consequence of the described changes in
the amounts of calpains and calpastatin in the elderly
lymphocytes, and whether they might be cause or rather
effect of these cells entering immunosenescence. Basedon our early paper we can conclude that decreased
amount of the enzymes directly corresponds to their
decreased available activity [14]. This notion is
corroborated by our observations of increased levels
of their important endogenous substrate – the D1
cyclins [20] - in the CD4+ lymphocytes of the elderly,
correlated with significantly shorter time required by
these cells to complete the mitotic cycle [19]. It was
also suggested, that retention of high levels of D1
cyclin prevents cells from entering the S phase, reducing
their proliferation [32], which may be the case for elderly
T cells exhibiting reduced CCS. On the other hand,
calpain activity is known to be conductive for either
increased apoptosis or apoptosis escape of different cell
types [7-10,14]. It is well known that the CD4+ cells of the
elderly are relatively resistant to apoptosis, which
could be interpreted as at least in part dependent of
decreased pro-apoptotic activity of lower amounts of
calpains seen in these cells.
A necessary precondition of intracellular activation of
calpains is the elevation of cytoplasmatic ionized calcium
level above its resting values. It is well known that this
‘calcium signal’ is decreased in the stimulated T cells and
other leukocytes of old individuals [33,34]. This decrease
may result in lower ‘attainable’ activity of μ- and
especially m-calpain (the latter requiring 100 micro- to 1
millimolar Ca2+ for its activation in vitro, and similar
calcium concentration in vivo [1-3,35]) in activated T
cells of old individuals, in turn leading to decrease of
(activation-dependent) apoptosis of these cells. The latter
paper points at an interesting effect of m-calpain activity
in the T cells, i.e. specific participation in the movements
(migration) of these cells [35]. It is thus possible, that
lack of calpain (and its activity) in the T cells of old
individuals may impair migration, and in consequence
tissue infiltration by these cells upon activation.
What would be the reason for lower amounts of the
CCS member proteins in the T cells of elderly? The most
obvious seems to be the decreased transcriptional activity
of the relevant genes. However, in a preliminary experi-
ment we were unable to show that this decrease in calpain
protein amount and activity is related to decreased level of
the calpain genes’ (CANP) transcription. Also, we did not
see any age-dependent change in CANP transcription
levels in non-transformed human lymphocytes in the
previous paper [14]. On the other hand, the activity of
calpains is self-limiting, in the sense that activated calpain
is its own substrate; thus, intracellular activation of calpain
would lead in time to the reduction of its amount [3,10],
which we in fact observed for the lymphocytes of elderly.
This explanation would, however, require some prior level
of endogenous activity of calpains; again, in a preliminary
experiment using the technique we described earlier for
measuring endogenous activity of calpains ex vivo as
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of calpain activity (as endogenous calpastatin degradation)
in the T cells of old, but not young people. Support to the
hypothesis of endogenous activation of calpains in the T
cells of elderly, possibly leading to decreased amounts of
the enzyme that we observe in these cells, is lent by
observation of increased “resting” Ca2+ in both T cells and
neutrophils of elderly, interpreted by these authors as
‘priming’ (i.e., early stage of activation) of these cells [33,34].Conclusions
Our findings suggest that the decrease of CCS (μ- and
m-calpain and calpastatin) expression in the T lymphocytes
with advanced age is universal but more pronounced for
the CD8+ lymphocytes, possibly affecting their function in
the aged. Further studies are required to elucidate both the
mechanism of the observed decreases in CCS expression
and its role in impaired function of old T lymphocytes. We
believe that these preliminary findings lend momentum
to the more detailed study of the relation between
CCS expression and activities in the lymphocytes and
human longevity.
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